Based on these encouraging results, the currently ongoing DOCTOS trial (doxapram conversion to sinus rhythm; EudraCT No: 2018-002979-17) was started, which investigates whether the FDA and EMA approved K2P3.1 (TASK-1) inhibitor doxapram can cardiovert AF in patients [2,179]. The gene discussed is KCNK3; the disease is atrial fibrillation.